New ketamine study promises extended relief for depression
Roughly 10 percent of the U.S. population is afflicted with major depressive disorder at any given time, and up to 20 percent will exhibit MDD symptoms over their lifetimes. Yet… read more.
Roughly 10 percent of the U.S. population is afflicted with major depressive disorder at any given time, and up to 20 percent will exhibit MDD symptoms over their lifetimes. Yet… read more.
Purdue University’s College of Pharmacy is now home to the Center for Research Innovation in Biotechnology and the Clinical Drug Experience Knowledgebase, a comprehensive database of every active pharmaceutical ingredient with evidence of… read more.
Among patients with ongoing, uncontrolled hypertension in spite of treatment with indapamide, amlodipine, or olmesartan, the addition of a single dose of investigative zilebesiran has, at 3 months,… read more.
In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be… read more.
Antidepressants that suppress REM (rapid eye movement) sleep appear to improve survival in people with amyotrophic lateral sclerosis (ALS). Researchers reported the finding on May 21, 2025 at… read more.
AbbVie announced the FDA has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the European Commission… read more.
April was a bumper month for drug approvals in Europe, with sixteen new products recommended by the European Medicines Agency’s (EMA) key committee on human medicines. This almost… read more.
While prednisone is the standard first-line treatment for pulmonary sarcoidosis, side effects can diminish quality of life. Researchers report that methotrexate appears to have fewer side effects and… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Veklury. The CHMP adopted… read more.
Teva Pharmaceutical Industries Ltd. , and Samsung Bioepis Co., Ltd. announced the availability of Epysqli (eculizumab-aagh) in the U.S. Epysqli is a biosimilar to Soliris (eculizumab) for the… read more.
A preclinical study from scientists at Scripps Research finds that a drug already FDA-approved for treating inflammatory conditions may help reduce both alcohol intake and pain sensitivity—two issues… read more.
Pfizer announced that the FDA accepted for review a Biologics License Application (BLA) for MenABCWY, its investigational pentavalent meningococcal vaccine candidate. Pfizer submitted MenABCWY for the prevention of… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.